[go: up one dir, main page]

IN2012DN05143A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05143A
IN2012DN05143A IN5143DEN2012A IN2012DN05143A IN 2012DN05143 A IN2012DN05143 A IN 2012DN05143A IN 5143DEN2012 A IN5143DEN2012 A IN 5143DEN2012A IN 2012DN05143 A IN2012DN05143 A IN 2012DN05143A
Authority
IN
India
Prior art keywords
present
glioma
tbs40
nfl
peptide
Prior art date
Application number
Inventor
Joel Eyer
Alan Peterson
Julien Balzeau
Raphael Berges
Original Assignee
Univ Angers
Inst Nat Sante Rech Med
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Angers, Inst Nat Sante Rech Med, Univ Mcgill filed Critical Univ Angers
Publication of IN2012DN05143A publication Critical patent/IN2012DN05143A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/57557—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides a new drug to treat malignant glioma, which is the most prevalent 1 type of primary tumor of the central nervous system (CNS). The present invention indeed shows that the isolated NFL-TBS40-63 peptide is highly specific for glioma cells, in which it triggers apoptosis. It is therefore presented here for use in a method for treating malignant glioma. The present invention further relates to the use of the NFL-TBS40-63 peptide for detecting specifically glioma cells either in vivo, or in vitro, or for addressing chemical compounds to said tumor cells.
IN5143DEN2012 2009-12-14 2010-12-14 IN2012DN05143A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28620709P 2009-12-14 2009-12-14
EP09306227A EP2332560A1 (en) 2009-12-14 2009-12-14 Use of a neurofilament peptide for the treatment of glioma
PCT/EP2010/069663 WO2011073207A1 (en) 2009-12-14 2010-12-14 Use of a neurofilament peptide for the treatment of glioma

Publications (1)

Publication Number Publication Date
IN2012DN05143A true IN2012DN05143A (en) 2015-10-23

Family

ID=42133636

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5143DEN2012 IN2012DN05143A (en) 2009-12-14 2010-12-14

Country Status (7)

Country Link
US (2) US9446092B2 (en)
EP (2) EP2332560A1 (en)
JP (1) JP5806679B2 (en)
CN (1) CN102821777B (en)
CA (1) CA2784091C (en)
IN (1) IN2012DN05143A (en)
WO (1) WO2011073207A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2869909B1 (en) * 2004-05-04 2007-12-21 Univ Angers PEPTIDE CAPABLE OF INHIBITING TUBULIN POLYMERIZATION AND USE THEREOF FOR INHIBITING CELL PROLIFERATION
EP2959913A1 (en) * 2014-06-23 2015-12-30 Universite D'angers Use of a neurofilament peptide for targeting neural stem cells
JP6612063B2 (en) * 2015-06-11 2019-11-27 国立大学法人滋賀医科大学 Malignant glioma molecule targeting peptide
US10550388B2 (en) * 2017-08-15 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Targeting pleiotrophin signaling to limit high-grade glioma invasion
CN108490191B (en) * 2018-03-13 2019-04-16 首都医科大学附属北京地坛医院 Application of neurofilament protein light chain in blood detection of syphilis
CN113195005B (en) * 2018-10-12 2023-07-21 国际先进加速器应用公司 Pharmaceutical compositions comprising radiolabeled GRPR antagonists and surfactants
CN112824427B (en) * 2019-11-18 2022-06-24 杨小骏 Short peptide for inhibiting glioma and application thereof
WO2024068999A1 (en) * 2022-09-30 2024-04-04 Gliocure Pharmaceutical composition comprising nfl-tbs40-63 peptide, variants or salts thereof and alanine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2869909B1 (en) 2004-05-04 2007-12-21 Univ Angers PEPTIDE CAPABLE OF INHIBITING TUBULIN POLYMERIZATION AND USE THEREOF FOR INHIBITING CELL PROLIFERATION

Also Published As

Publication number Publication date
CN102821777B (en) 2014-12-17
CA2784091C (en) 2020-08-11
WO2011073207A1 (en) 2011-06-23
JP5806679B2 (en) 2015-11-10
CA2784091A1 (en) 2011-06-23
US20170000846A1 (en) 2017-01-05
US20130004429A1 (en) 2013-01-03
EP2512499B1 (en) 2015-09-16
EP2332560A1 (en) 2011-06-15
JP2013513646A (en) 2013-04-22
US9446092B2 (en) 2016-09-20
CN102821777A (en) 2012-12-12
EP2512499A1 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
IN2012DN05143A (en)
EA201270049A1 (en) DESIGNED PHTHALASINE ANTAGONISTS WAYS HEDGEHOG
SA515360657B1 (en) Histone demethylase inhibitors
NO20091661L (en) Use of pegylated IL-10 to treat cancer
EA201291107A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
MY184882A (en) Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathyway inhibitors
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
TN2009000323A1 (en) Modulators of sclerostin binding partners for treating bone-related disorders
MX2010002312A (en) Triazolopyridine compounds and their use as ask inhibitors.
WO2010017515A3 (en) Breast cancer specific markers and methods of use
SI1802625T1 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
EA200970403A1 (en) BICYCLIC TRIAZOLES AS PROTEINKINASE MODULATORS
WO2008005954A3 (en) Tryphostin-analogs for the treatment of cell proliferative diseases
MX2009008461A (en) Genetic variants contributing to risk of prostate cancer.
EP3106168A3 (en) Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
MX2009011346A (en) Tapentadol for treating pain from arthritis.
UA102115C2 (en) Disubstituted phthalazine hedgehog pathway antagonists
MX349550B (en) 1, 7 - diazacarbazoles and their use in the treatment of cancer.
GEP20125647B (en) Kinesin inhibitors as cancer therapeutics
EP2416795A4 (en) Inhibitors of cognitive decline
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
MX2007016469A (en) Methods of treatment using hydroquinone ansamycins.
GB0718878D0 (en) Photodynamic Theraphy and diagnosis
MX2010000956A (en) Compounds which inhibit beta-secretase activity and methods of use thereof.
WO2012009663A3 (en) New compounds for treating cancer and other diseases